IDH.L Regulatory News (IDH)

2 July 2012

Immunodiagnostic Systems Holdings plc

Patrick Dahlen Appointed as Chief Executive Officer

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, today announces that Patrik Olof Dahlen, a current Non-executive member of the Board, has been appointed Chief Executive Officer with immediate effect. 

Patrik, aged 50, has substantial diagnostic and international industry expertise gained as Chief Executive Officer of Dako and at Perkin Elmer through to his progression to President of Life Sciences. At Dako, Patrik conducted a significant strategic repositioning of the company as a cancer diagnostics provider and a leader in companion diagnostics. As President of Life Sciences at Perkin Elmer, Patrik was instrumental in building the company's diagnostic business with a niche focus on diagnostic systems for neonatal and prenatal screening.

Most recently, Patrik acted as CEO for Neurosearch with the specific task of optimising the commercialisation strategy and establishing a global partnership for the Company's lead product, Huntexil®.

Dr Antony Martin, Non-executive Chairman of Immunodiagnostic Systems, said: "I am delighted that Patrik has stepped up to the role of Chief Executive Officer. Patrik brings a wealth of international diagnostics expertise which the Board has been benefiting from in his capacity as a Non-executive Director and we look forward to working with Patrik in the continued development and execution of the next phase of growth at IDS."

The following disclosures are made in accordance with AIM rule 17 and Schedule 2 paragraph (g) of the AIM Rules:

Patrik Dahlen is currently a director of QuantiBact A/S and DiaGenic ASA and in the last five years has been a director of Dako A/S, Chempaq A/S, NeuroSearch A/S, Sophion Biosciences A/S, Olink AB, Proxeon A/S and Contura A/S.

Patrik Dahlen has a beneficial interest in 19,032 IDS ordinary shares.

For further information: